Shares of Peregrine Pharmaceuticals soared up to 33% intraday before closing with a still impressive 19% gain, thanks to the announcement that the FDA green-lit bavituximab's phase 3 non-small-cell lung cancer trial.
In this video, health-care analyst David Williamson discusses whether the FDA decision justified this type of bullish enthusiasm and whether Peregrine is doing right by investors in starting this trial, given bavituximab's phase 2 troubles.
Another topic health-care investors need to keep up on is Obamacare, as the law will undoubtedly have far-reaching effects. The Motley Fool's new free report, "Everything You Need to Know About Obamacare," lets you know how your health insurance, your taxes, and your portfolio will be affected. Click here to read more.
Follow David on Twitter: @MotleyDavid.